Page 5 - Zydus Lifesciences

Stocks to Watch on Sept 21: Infosys, Sheela Foam, SJVN, Cipla, DCB Bank

Stocks to Watch today, September 21, 2023: The government will sell up to 4.9 per cent stake in SJVN via offer for sale (OFS) on Thursday and Friday

Zydus Lifesciences gets USFDA nod for pregnancy prevention medication

The company said that this is the third hormonal transdermal patch to be approved from Zydus' generics portfolio

How India has been supplying quality drugs affordably to the entire world

With Indian innovation coming into its own and the Indian pharma industry ushering in a new wave of healthcare concepts, we will see India strengthening its position as the pharmacy to the world

Zydus Lifesciences gets USFDA nod for generic acne treatment drug

Zydus Lifesciences on Thursday said it has received approval from the US health regulator to market a generic product to treat acne in the American market. The drug firm has received final approval from the US Food and Drug Administration (USFDA) for Isotretinoin Capsules USP (10 mg, 20 mg 30 mg and 40 mg), it said in a statement. Isotretinoin capsules are used to treat severe cystic acne that has not responded to other treatments. The drug will be manufactured at Zydus' formulation manufacturing facility in Moraiya, Ahmedabad. As per the IQVIA MAT data, Isotretinoin Capsules had annual sales of USD 165 million in the US. Shares of Zydus Lifesciences were trading 0.13 per cent down at Rs 627.35 apiece on the BSE.

Stocks to Watch: Torrent Pharma, Cipla, TVS Supply Chain, Titan, AdaniTotal

Stocks to Watch on August 23, 2023: Torrent Pharma has joined the race to buy out Cipla's promoter stake held by the Hamied family, reported The Economic Times

ACC, HDFC AMC, three other companies to be excluded from Nifty Next 50

Five firms, including ACC Ltd, HDFC Asset Management Company and FSN E-Commerce Ventures that runs Nykaa, will be dropped from Nifty Next 50 index from September 29. NSE Indices Ltd, an arm of the National Stock Exchange, on Thursday said that Indus Towers and Page Industries will also be dropped from the index. Punjab National Bank, Trent, Sriram Finance, TVS Motor Company, and Zydus Lifesciences will be included in the Nifty Next 50 index, NSE Indices said in a statement. NSE Indices' Index Maintenance Sub-Committee (IMSC) decided to make the changes with effect from September 29 as a part of a semi-annual review. In addition, changes have been announced in several indices -- Nifty 500, Nifty 100, Nifty Midcap 150, Nifty Small Cap 250, Nifty Midcap 50, Nifty Midcap 100, Nifty Smallcap 50, and Nifty Smallcap 100. However, no changes were announced in the NSE's benchmark index Nifty 50. NSE Indices also revised the eligibility criteria for several sectoral indices, including Nift

Zydus Lifesciences gets USFDA nod for generic rheumatoid arthritis drug

Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture and market its generic Indomethacin suppositories indicated for moderate to severe rheumatoid arthritis. The approval by the US Food and Drug Administration (USFDA) is for manufacturing and marketing of Indomethacin suppositories of 50mg strength, the company said in a regulatory filing. The company has been granted 180-day CGT (competitive generic therapy) exclusivity to market this product, it added. As per the USFDA, it may designate a drug as a CGT after determining that there is inadequate generic competition for that drug. "We are happy to leverage the CGT approval pathway of the USFDA to provide patients with expanded access to a product with limited competition," Zydus Lifesciences Managing Director Dr Sharvil Patel said. Zydus said Indomethacin suppositories is a non-steroidal, anti-inflammatory drug indicated for moderate to severe rheumatoid arthritis inclu

Zydus gets USFDA nod to market cancer treatment generic injection

Zydus Lifesciences on Thursday said it has received approval from the US health regulator to market a cancer treatment generic injection in the American market. The company has received final approval from the USFDA for Plerixafor injection, which is used by patients with certain types of cancer to prepare them for stem cell transplant, Zydus Lifesciences said in a statement. The drug will be manufactured at the group's injectable manufacturing facility at Ahmedabad, it added. As per IQVIA MAT May 2023 data, Plerixafor injection single-dose vials had annual sales of USD 210 million in the US. Shares of Zydus were trading 4.39 per cent up at Rs 649.80 apiece on the BSE.

We want to become the no. 1 diagnostics provider in the world: Mylab MD

'The Mylab ecosystem is capable of providing solutions'

Stocks to watch: Adani Transmission, HDFC AMC, ITC, Sun Pharma, Coal India

Stocks to watch on June 20, 2023: From HDFC AMC to Adani Transmission, here are few stocks to watch in Tuesday's trading session

Zydus Lifesciences gets USFDA nod for generic acne-treating drug

Zydus Lifesciences on Monday said it has received final approval from the US health regulator for its generic antibiotic Minocycline Hydrochloride extended-release tablets used for treatment of moderate to severe acne. The approval granted by the US Food and Drug Administration (USFDA) is for Minocycline Hydrochloride extended-release tablets of strengths 55 mg, 65 mg, and 115 mg, Zydus Lifesciences said in a regulatory filing. The tablet is used for treatment of moderate to severe acne in people aged 12 years and above. The product will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad, the company said.

Stocks to Watch today, June 14: Adani Group, Zee, RIL, Maruti, SBI Life

Stocks to watch on June 14, 2023: BHEL, Delta Corp, Indiabulls Housing Finance, IEX, India Cements and Manappuram Finance are the six stocks in F&O ban period today.

Zydus Lifesciences gets USFDA nod for anti-smoking and arthritis drugs

The stock for Zydus Lifesciences rose 1.52 percent on BSE to Rs 517.70 per share

Zydus Lifesciences gets USFDA nod to mfg generic version of Varenicline

Zydus Lifesciences on Tuesday said it has received final approval from the US health regulator to manufacture and market the generic version of Varenicline tablets indicated to treat smoking addiction. The approval by the US Food and Drug Administration (USFDA) is for Varenicline tablets of strengths 0.5 mg and 1 mg, Zydus said in a regulatory filing. The product will be launched shortly. It will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India, it added. Varenicline tablets, 0.5 mg and 1 mg had annual sales of USD 501 million in the US, the company said citing IQVIA MAT March 2023 data.

Zydus Lifesciences receives final USFDA approval for varenicline tablets

The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ

Zydus begins Phase-IV trial for non-alcoholic fatty liver disease drug

Saroglitazar Mg has been studied in two well-controlled Phase 3 clinical trials in patients with NAFLD and NASH in India

Zydus receives final approval from USFDA for esomeprazole magnesium

Esomeprazole magnesium for delayed-release oral suspension, 20 mg and 40 mg had annual sales of $42 mn in the United States

Stocks to Watch today, June 8: Banks, Auto, Lemon Tree, Adani Ent, Titagarh

Stocks to Watch on June 8, 2023: Shares of banks, automobile, and real estate companies could see considerable action in Thursday's session as the Reserve Bank of India (RBI) is slated to announce its

Zydus Lifesciences Q4 consolidated net profit dips 25.36% to Rs 296.6 cr

Zydus Lifesciences Ltd on Thursday reported a 25.36 per cent decline in consolidated net profit at Rs 296.6 crore in the fourth quarter ended March 31, 2023 impacted by impairment of goodwill of a wholly-owned subsidiary. The company, which had posted a consolidated net profit of Rs 397.4 crore in the same quarter of the previous fiscal, said its board has recommended a final dividend of Rs 6 per equity share of Re 1 each, subject to approval of shareholders at the Annual General Meeting scheduled to be held on August 11, 2023. Consolidated total revenue from operations stood at Rs 5,010.6 crore, as against Rs 3,805.6 crore in the corresponding period a year ago, Zydus Lifesciences said in a regulatory filing. Total expenses were higher at Rs 3,961.3 crore, as compared to Rs 3,311.8 crore in the year-ago quarter. During the quarter, Zydus Lifesciences said it incurred an exceptional item of Rs 594.1 crore as impairment of goodwill by Sentynl Therapeutics Inc, a wholly-owned subsidi

Zydus Lifesciences gets final approval from USFDA to manufacture ulcer drug

Sucralfate Tablets USP, 1 gram had annual sales of $84 million in the United States